Project Grant R01DK145849
- Federal Project Grant Award Summary The University of Virginia received a $782,459 Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), effective March 1, 2026 through February 28, 2031. This five-year research initiative investigates the mechanisms by which obesity exacerbates cardiovascular disease (CVD) risk in individuals with Type 1 Diabetes (T1D) by...
- Federal Grant Award Summary Virginia Commonwealth University received a $177,350 Project Grant from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), effective September 1, 2025 through August 31, 2030. The grant supports research to advance sacral neuromodulation (SNM) treatment for overactive bladder (OAB) through development of objective analytics and predictive tools....
- Federal Grant Award Summary The University of Virginia received a $829,985 Project Grant from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), awarded July 1, 2025, with completion targeted for April 30, 2030. This award supports the development and utilization of new Drosophila (fruit fly), mouse, and human podocyte models to investigate the molecular mechanisms by which...
- Federal Project Grant Award Summary The University of California, San Francisco received a $192,215 Project Grant from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), awarded July 15, 2025, with completion scheduled for March 31, 2030. This research initiative will develop and implement a risk communication tool designed to improve treatment persistence with sodium-glucose...
- Federal Grant Award Summary The Jaeb Center for Health Research Foundation, Inc. received a $2.34M Project Grant from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) on September 3, 2025, to conduct research on implementing patch hybrid closed-loop (HCL) insulin delivery systems for cognitively impaired older adults with Type 1 Diabetes. The three-year research initiative,...
- Federal Grant Award Summary The University of Minnesota received a $308,000 Project Grant from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), awarded February 1, 2026, with completion targeted for December 31, 2028. This pilot clinical trial investigates the efficacy and safety of sodium-glucose cotransporter 2 inhibitor (SGLT2i) therapy in islet autotransplant recipients...
- Federal Grant Award Summary The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) awarded the Regents of the University of Michigan a $681,562 Project Grant on July 21, 2025, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847). This award supports a research initiative focused on promoting metabolic maturity of islet organoids derived from human pluripotent stem cells (HPSC) for Type 1 Diabetes treatment. The research addresses a...
- Federal Grant Award Summary The University of Michigan received a $769,155 Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), effective September 12, 2025, through July 31, 2030. The award funds the Michigan Diabetes Project, a research initiative designed to develop and evaluate a virtually administered, evidence-based diabetes self-management support (DSMS)...
- Federal Grant Award Summary The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) awarded $188,632 to the University of Kansas Medical Center Research Institute under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) effective August 1, 2025, through July 31, 2030. This project grant supports the development and pilot testing of the Rural Emerging/Young Adult Collaborative Care—Type 1 Diabetes (REACT-T1D) program, designed to address...
- Federal Project Grant Award Summary The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) awarded the University of Virginia $162,476 on June 3, 2025, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to conduct research on renin cell identity and function. The project, titled "The Reninness Score: Integrative Analysis of Multi-Omic Data to Define Renin Cell Identity," will be completed by December 31, 2026. The research...
The University of Virginia received a $788,831 Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), effective February 1, 2026 through December 31, 2029. The award funds development of a ketone-aware automated insulin delivery (AID) system designed to enable safe use of sodium-glucose cotransporter inhibitors (SGLT1) in patients with Type 1 Diabetes (T1D). The research addresses a critical clinical gap by integrating continuous ketone monitoring (CKM) and continuous glucose monitoring (CGM) into closed-loop insulin delivery systems through a refined ketone-aware predictive algorithm (KAPA). The project delivers an innovative therapeutic technology that combines dual-input sensor data to optimize glycemic control while minimizing ketosis risk—a significant safety concern that has limited SGLT1 medication use in the T1D population despite demonstrated cardiorenal benefits. The research conducted at the University of Virginia in Charlottesville will advance diabetes management technology by enabling clinicians to leverage cardioprotective and renal-protective medications more safely through automated insulin delivery systems informed by real-time ketone monitoring, thereby improving treatment options and reducing disease progression risks for patients with Type 1 Diabetes.Federal Grant Award Summary
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $788.8k | 1/31/26 |